Difference between revisions of "Team:XJTLU-CHINA/Applied Design"
| Line 29: | Line 29: | ||
<h1>Dairy product</h1> | <h1>Dairy product</h1> | ||
<p style="font-size:20px"> | <p style="font-size:20px"> | ||
| − | Yogurt has been an everyday dairy product | + | Yogurt has been an everyday dairy product which can improve human intestinal health. Our blueprint |
| − | is to combine the benefits of yogurts as a daily commodity and the effectiveness of | + | is to combine the benefits of yogurts as a daily commodity and the effectiveness of antimicrobial peptides |
| − | to serve as an intestine disease | + | to serve as an intestine disease targeted therapy. The yogurt itself has a very obvious advantages in providing |
| − | a large quantity of probiotics | + | a large quantity of probiotics which can inhibit the growth of bad bacteria in the guts while keeping the |
good bacteria on work. In addition, | good bacteria on work. In addition, | ||
| − | <i>Lactococcus lactis </i>will function as | + | <i>Lactococcus lactis </i>will function as an ideal host of antimicrobial peptides. Firstly, it is rather |
| − | common in yogurt. In addition, the probiotics | + | common to be present in yogurt. In addition, the probiotics can reproduce in a rapid pace to accumulate and manufacture |
| − | + | enough antimicrobial peptides to be effective. The metabolic pathways of | |
| − | <i> L. | + | <i> L. lactis</i> is also well-known and will not produce some toxins outside the probiotics to give undesirable |
| − | + | side effects. Most importantly, | |
| − | <i>L. | + | <i>L. lactis </i>will only release the antimicrobial peptides once it gets in touch with a specific pathogen, which minimizes |
the possibilities of antibiotics resistance. | the possibilities of antibiotics resistance. | ||
</p> | </p> | ||
| Line 45: | Line 45: | ||
<div class="para"> | <div class="para"> | ||
| − | <h1>Reduction on | + | <h1>Reduction on antibiotic resistance</h1> |
<p style="font-size:20px"> | <p style="font-size:20px"> | ||
| − | Antibiotics have been very popular for its treatment of many serious | + | Antibiotics have been very popular for its treatment of many serious infections, say, in our case, human intestinal diseases. |
| − | Antibiotics | + | Antibiotics exert their effects via several mechanisms. They can either kill pathogens by damaging their cell wall |
| − | or cell membrane structure, inhibiting | + | or cell membrane structure, inhibiting normal protein and nucleic acid synthesis or interfering with |
| − | + | their metabolic pathways. Unfortunately, some pathogens will conjure some slippery tricks to help themselves to | |
survive, proliferate and eventually become highly resistant to the antibiotics, such as producing some new | survive, proliferate and eventually become highly resistant to the antibiotics, such as producing some new | ||
| − | mutations rapidly or | + | mutations rapidly or acquiring genetic-makeups from old bacteria which have antibiotic resistance. In |
| − | order to handle the problem of antibiotics resistance, we got | + | order to handle the problem of acquiring antibiotics resistance, we got inspiration from the technique used in the cocktail treatment for |
| − | + | HIV infection, in which different drugs targeting different parts/proteins of HIV are used in impeding the HIV replication | |
| − | and cell infection. Similarly, our idea | + | and cell infection. Similarly, our idea hopes to use a multiple kinds of antimicrobial peptides to attack the pathogens |
simultaneously in different parts of the bacteria. Therefore, only when the bacteria produce several mutations | simultaneously in different parts of the bacteria. Therefore, only when the bacteria produce several mutations | ||
| − | in the different | + | in the different structures simultaneously can it survive the antimicrobial attack. Simultaneous mutation in 3 different proteins/structures is |
| − | very difficult | + | very difficult and unlikely to happen. If |
| − | there is only one | + | there is only one mutation that leads to the resistance to an antimicrobial peptide, the bacteria |
will still be killed by other classes of antimicrobial peptides. And that's how our project works. Our | will still be killed by other classes of antimicrobial peptides. And that's how our project works. Our | ||
<i> | <i> | ||
| − | L. | + | L. lactis </i>will produce many kinds of different-functioned antimicrobial peptides working together to realize |
| − | a "cocktail" effect. In other words, there will be a higher genetic barrier | + | a "cocktail" effect. In other words, there will be a higher genetic barrier for the bacteria to gain resistance. |
| − | Another advantage of our project is that antimicrobial peptides will only be released as soon as | + | Another advantage of our project is that antimicrobial peptides will only be released as soon as |
| − | <i>L. | + | <i>L. lactis </i> detects <i>Staphylococcus aureus</i>, which can wisely control the drug dosage under an appropriate quantity |
depending on the patients' own condition, and thus effectively alleviate the problem of antibiotic overuse | depending on the patients' own condition, and thus effectively alleviate the problem of antibiotic overuse | ||
| − | that will cause resistance | + | that will cause resistance. |
| − | + | ||
| − | + | ||
| − | + | ||
</p> | </p> | ||
</div> | </div> | ||
Revision as of 07:12, 1 November 2017
Application
Dairy product
Yogurt has been an everyday dairy product which can improve human intestinal health. Our blueprint is to combine the benefits of yogurts as a daily commodity and the effectiveness of antimicrobial peptides to serve as an intestine disease targeted therapy. The yogurt itself has a very obvious advantages in providing a large quantity of probiotics which can inhibit the growth of bad bacteria in the guts while keeping the good bacteria on work. In addition, Lactococcus lactis will function as an ideal host of antimicrobial peptides. Firstly, it is rather common to be present in yogurt. In addition, the probiotics can reproduce in a rapid pace to accumulate and manufacture enough antimicrobial peptides to be effective. The metabolic pathways of L. lactis is also well-known and will not produce some toxins outside the probiotics to give undesirable side effects. Most importantly, L. lactis will only release the antimicrobial peptides once it gets in touch with a specific pathogen, which minimizes the possibilities of antibiotics resistance.
Reduction on antibiotic resistance
Antibiotics have been very popular for its treatment of many serious infections, say, in our case, human intestinal diseases. Antibiotics exert their effects via several mechanisms. They can either kill pathogens by damaging their cell wall or cell membrane structure, inhibiting normal protein and nucleic acid synthesis or interfering with their metabolic pathways. Unfortunately, some pathogens will conjure some slippery tricks to help themselves to survive, proliferate and eventually become highly resistant to the antibiotics, such as producing some new mutations rapidly or acquiring genetic-makeups from old bacteria which have antibiotic resistance. In order to handle the problem of acquiring antibiotics resistance, we got inspiration from the technique used in the cocktail treatment for HIV infection, in which different drugs targeting different parts/proteins of HIV are used in impeding the HIV replication and cell infection. Similarly, our idea hopes to use a multiple kinds of antimicrobial peptides to attack the pathogens simultaneously in different parts of the bacteria. Therefore, only when the bacteria produce several mutations in the different structures simultaneously can it survive the antimicrobial attack. Simultaneous mutation in 3 different proteins/structures is very difficult and unlikely to happen. If there is only one mutation that leads to the resistance to an antimicrobial peptide, the bacteria will still be killed by other classes of antimicrobial peptides. And that's how our project works. Our L. lactis will produce many kinds of different-functioned antimicrobial peptides working together to realize a "cocktail" effect. In other words, there will be a higher genetic barrier for the bacteria to gain resistance. Another advantage of our project is that antimicrobial peptides will only be released as soon as L. lactis detects Staphylococcus aureus, which can wisely control the drug dosage under an appropriate quantity depending on the patients' own condition, and thus effectively alleviate the problem of antibiotic overuse that will cause resistance.
Collaborators and Supporters
